Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $949.59 MXN
Change Today 0.00 / 0.00%
Volume 0.0
MRK* On Other Exchanges
Symbol
Exchange
New York
Mexico
EN Paris
Sao Paulo
Frankfurt
As of 4:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by MERCK & CO. INC. (MRK*) in the last 6 months

Announced 07/28/15
605.00M for cCAM Biotherapeutics Ltd.
Merger/Acquisition

Merck & Co. Inc. (NYSE:MRK) signed a definitive agreement to acquire cCAM Biotherapeutics Ltd. from Arkin Holdings, OrbiMed Israel Partners, a fund managed by OrbiMed Advisors, L.L.C., Pontifax and others shareholders for approximately $610 million in cash on July 28, 2015. An upfront payment of $95 million will be done. As part of consideration, cCAM shareholders are eligible to receive up to $510 million associated with the attainment of certain clinical development, ...
Read More


MRK*'s price was unchanged after the transaction was announced on 07/28/15.
Investor / Buyer
Merck & Co. Inc.
Creditor / Lender
Arkin Holdings
Meytav Technological Incubator
OrbiMed Advisors, L.L.C.
OrbiMed Israel Partners
Pontifax Ltd.
Roche Holding AG
 
Announced 04/9/15
Merck & Co. Inc., Manufacturing Facility In Arecibo
Merger/Acquisition

American Industrial Acquisition Corporation signed an agreement to acquire the manufacturing facility in Arecibo from Merck & Co. Inc. (NYSE:MRK) on April 9, 2015. American Industrial Acquisition Corporation will retain the approximately 200 Merck employees at the Arecibo manufacturing facility.


MRK*'s price was unchanged after the transaction was announced on 04/9/15.
Investor / Buyer
American Industrial Acquisition Corporation
Creditor / Lender
Merck & Co. Inc.
 
Announced 04/7/15
Arvinas, Inc.
Private Placement

Arvinas, Inc. announced that it will receive funding from new investor Merck & Co., Inc. on April 7, 2015. The terms of the transaction were not disclosed.


MRK*'s price was unchanged after the transaction was announced on 04/7/15.
Investor / Buyer
Merck & Co. Inc.
 
Announced 03/24/15
10.00B for Merck & Co. Inc.
Buyback

Merck & Co. Inc. (NYSE:MRK) announces a share repurchase program. Under the program, the company will repurchase up to $10,000 million worth of common stock. The repurchases will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. The shares will be repurchased for its treasury. The program reinforces company's commitment to deliver increased value to the shareholders and the Board's confidence ...
Read More


MRK*'s price was unchanged after the transaction was announced on 03/24/15.
 
Announced 02/23/15
106.00M for NGM Biopharmaceuticals, Inc.
Private Placement

NGM Biopharmaceuticals, Inc. announced that it will receive $106 million from new investor Merck & Co. Inc. on February 23, 2015. The investor will acquire 15% stake in the company. The round will be raised at a post-money valuation of $706 million. The funding raised will represent 20% premium to NGM’s most recent financing. The company has issued convertible series E preferred stock Pursuant to Regulation D.


MRK*'s price was unchanged after the transaction was announced on 02/23/15.
Investor / Buyer
Merck & Co. Inc.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK*:MM $949.59 MXN 0.00

MRK* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $151.57 USD +0.12
Amgen Inc $171.69 USD +0.22
Bayer AG €133.88 EUR -1.75
Gilead Sciences Inc $117.90 USD +2.19
GlaxoSmithKline PLC 1,389 GBp +14.50
View Industry Companies
 

Industry Analysis

MRK*

Industry Average

Valuation MRK* Industry Range
Price/Earnings 17.1x
Price/Sales 4.1x
Price/Book 3.5x
Price/Cash Flow 16.8x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.